Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2023

02-08-2023 | Diffuse Large B-Cell Lymphoma | short review

Aggressive B cell lymphomas—highlights from ASH 2022

Author: Michael Panny

Published in: memo - Magazine of European Medical Oncology | Issue 3/2023

Login to get access

Summary

The treatment landscape of aggressive B cell lymphomas has changed substantially in recent years. Several therapeutic agents changed the dogma of diffuse large B cell lymphoma (DLBCL) as a one shot cancer. CD-19-targeted CART cell therapy, CD79b-targeted antibody drug conjugate polatuzumab vedotin, and CD 19 antibody tafasitamab in combination with lenalidomide are approved in relapsed/refractory (r/r) disease. Recently the bispecific CD20/CD3 antibody glofitamab received approval for third-line therapy and approval for other CD20/CD3 bispecific antibodies is expected soon. This short review is a personal selection of the clinically most relevant abstracts besides CART therapy regarding aggressive B cell lymphomas presented at the 2022 ASH meeting in San Diego.
Literature
1.
Illerhaus G et al. Effects on survival of non-myeloablative chemoimmunotherapy compared to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) as consolidation therapy in patients with primary cns lymphoma - results of an international randomized phase III trial (MATRix/IELSG43). Blood. 2022;140(suppl 2):LBA-3.
2.
Topp MS, et al. Glofitamab plus R‑CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B‑cell lymphoma (DLBCL): results from a phase Ib study. ASH 2022 abstract, Vol. 777. 2022.
3.
Abrisqueta P, et al. Subcutaneous Epcoritamab + R‑Dhax/C in patients with relapsed or refractory diffuse large B cell lymphoma eligible for autologous stem cell transplant: updated phase 1/2 results. ASH 2022 abstract, Vol. 443. 2022.
4.
Won-Seog K, et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B‑cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM‑2. ASH 2022 Abtract, Vol. 444. 2022.
5.
Dickinson MJ, et al. Glofitamab for relapsed or refractory diffuse large B‑cell lymphoma. N Engl J Med. 2022;387(24):2220–31.CrossRefPubMed
6.
Hutchings M, et al. Relapse is uncommon in patients with large B‑cell lymphoma who are in complete remission at the end of fixed-course Glofitamab treatment. ASH 2022 Abstract, Vol. 441. 2022.
7.
Kater AP, et al. Subcutaneous Epcoritamab in patients with richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). ASH 2022 abstract, Vol. 348. 2022.
8.
Duell J, et al. Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L‑MIND study. AACR 2023 abstract, Vol. CT022. 2023.
9.
Qualls D, et al. Tafasitamab and Lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): real world outcomes in a multicenter retrospective study. ASH 2022 abstract, Vol. 323. 2022.
Metadata
Title
Aggressive B cell lymphomas—highlights from ASH 2022
Author
Michael Panny
Publication date
02-08-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00908-y

Other articles of this Issue 3/2023

memo - Magazine of European Medical Oncology 3/2023 Go to the issue

short review

FlASHback—personal highlights regarding myelodysplastic syndrome from the 2022 ASH meeting

leading article

Emerging molecular drugs for the treatment of gastroesophageal tumors

short review

Lipid nanoparticles in the treatment of lung cancer—hype or hope?

editorial

Long-term survival and follow-up care after cancer in Austria

short review

Late complications after oncological therapy

short review

ASH highlights 2022—multiple myeloma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits